Patent Application
20120149652
A subject of the present invention is novel peptides transformed so as to comprise post-translational-type modifications, such as phosphorylation or acetylation of one or more amino acids. The invention also relates to processes for obtaining them, and their uses in pharmaceutical compositions within the framework of the treatment of autoimmune pathologies.
Several studies have shown the benefits of using synthetic peptides for the prevention in murine models of the development of autoimmune pathologies such as lupus. These studies have been carried out with peptides derived either from histone sequences, or from anti-DNA antibodies. The administration by intravenous route of these peptides has allowed a reduction in the production of anti-DNA antibodies typical of lupus and a prolongation of the survival of the treated mice. No study has been carried out based on protein sequences of the spliceosome, another lupus autoantigen.
The few studies carried out to date having shown an improvement of the pathology of lupus in autoimmune mice have used peptides not containing post-translational modifications (Eilat et al., 2000; Jouanne et al., 1999; Kaliyaperumal et al., 1999; Marino et al, 2000).
The post-translational modifications seem to play an important role in the emergence of the autoimmune response (Utz and Anderson, 1998). In order to establish effective intervention strategies, the identification of the targets which are really responsible for the rupture of the self-tolerance and then recognized by the autoreactive cells is a major benefit.
The identification of the sequences of the 70K protein recognized by the autoreactive T-cells began in 1998. The inventors firstly synthesized 20 overlapping peptides covering the sequence of the 70K protein and studied recognition of these peptides by the antibodies of MRL/lpr lupic mice and by the autoreactive CD4+ T cells of these mice. Among these 20 peptides, they identified the peptide corresponding to the sequence 131-151 (RIHMVYSKRSGKPRGYAFIEY) of the 70K protein recognized very early by the antibodies of these mice (Monneaux et al, 2000). This peptide is capable of stimulating in vitro the proliferation and the secretion of IL-2 by the CD4+T cells purified from the ganglia.
Subsequently, the inventors showed that this sequence also represented a major epitope of the 70K protein in another model of lupic mice, the NZB/W mouse (
The inventors then wished to determine the exact nature of the sequence of the 70K protein capable of activating the autoreactive T cells. The inventors synthesized several peptides corresponding to the phosphorylated and acetylated forms on the serine and lysine residues of the 131-151 peptide, and studied the ability of these peptides to be recognized by the T lymphocytes and the antibodies of lupic mice.
The present invention derives from the demonstration by the inventors that these phosphorylated and acetylated peptides are recognized to the same extent or even to a greater extent than the non-phosphorylated and non-acetylated parent peptide by the CD4+ T cells and the antibodies of lupic mice, and that the administration of these phosphorylated and acetylated peptides reduces the production of large amounts of antibodies directed against the DNA, delays the appearance of glomerulonephritis and prolongs the survival of the animals, while the parent peptide does not on the other hand induce any statistically significant effect.
An aim of the present invention is to provide novel peptides which can be used for the preparation of medicaments within the framework of the treatment of autoimmune diseases, and more particularly of lupus, which have the advantage of being clearly more effective than the peptides used to date, and not having major side effects such as those encountered with the current treatment techniques, to the extent that the modified peptides of the invention are specific to the deleterious cells and only target these cells, unlike the immunosuppressives, cytokines, or other molecules currently used which act on the immune system in a global fashion.
A subject of the invention is the use of peptides comprising epitopes of self-proteins of mammals recognized by antibodies produced by the immune system of mammals suffering from autoimmune pathologies, and, if appropriate, by the auxiliary T cells of said mammals, said epitopes being such that at least one of their amino acids comprises a post-translational modification, for the preparation of a medicament intended for the prevention or the treatment of said autoimmune pathologies.
By post-translational modification, is meant in the preceding and in the following, any type of modification of the amino acids of a given protein capable of being produced in vivo in the cells of the organism, such as the phosphorylation or acetylation processes or other processes.
A subject of the invention is more particularly the above-mentioned use of peptides as defined above, comprising epitopes in which at least one of their amino acids is modified in such a manner that it is in a phosphorylated, or acetylated form.
The invention more particularly relates to the above-mentioned use of peptides comprising epitopes originating from proteins of human or animal origin defined above, said proteins being chosen from the nucleoproteins, the proteins of the nucleosome, spliceosome, Ro ribonucleoproteic particle, or ribosome for example.
The invention also relates to the use of peptides as defined above, for the preparation of a medicament intended for the prevention or treatment:
A subject of the invention is more particularly the use of peptides as defined above, for the preparation of a medicament intended for the prevention or the treatment of SLE.
Therefore, the invention relates more particularly to the above-mentioned use of peptides comprising epitopes originating from the human or murine U1-70K protein of the spliceosome (described in particular in Klein Gunnewiek et al, 1997).
A subject of the invention is still more particularly the above-mentioned use of peptides comprising the sequence delimited by the 131 and 151 amino acids of the human or murine U1-70K protein, and corresponding to the following sequence SEQ ID NO: 1:
in which at least one of the amino acids comprises a post-translational-type modification, in particular in which at least one of the amino acids is phosphorylated, or acetylated.
The invention relates more particularly to the above-mentioned use of peptides comprising the sequence SEQ ID NO: 1 in which at least one of the serine residues in position 7 or 10 is phosphorylated, and/or at least one of the lysine residues in position 8 or 12 is acetylated.
A subject of the invention is more particularly the above-mentioned use of peptides comprising the sequence SEQ ID NO: 1 in which:
The invention relates still more particularly to the above-mentioned use of peptides chosen from the following:
A subject of the invention is still more particularly the above-mentioned use of peptides chosen from the following:
A subject of the invention is also any pharmaceutical composition characterized in that it comprises at least one peptide chosen from those defined above, in combination with a pharmaceutically acceptable vehicle.
A subject of the invention is more particularly any pharmaceutical composition as defined above, characterized in that it comprises at least one peptide chosen from those comprising the sequence SEQ ID NO: 1 in which at least one of the amino acids comprises a post-translational-type modification, in particular by phosphorylation, or acetylation.
The invention relates more particularly to any pharmaceutical composition as defined above, characterized in that it comprises at least one peptide chosen from those comprising the sequence SEQ ID NO: 1 in which at least one of the serine residues in position 7 or 10 is phosphorylated, and/or at least one of the lysine residues in position 8 or 12 is acetylated.
A subject of the invention is more particularly any pharmaceutical composition as defined above, characterized in that it comprises at least one peptide chosen from those comprising the sequence SEQ ID NO: 1 in which:
The invention relates still more particularly to any pharmaceutical composition as defined above, characterized in that it comprises at least one peptide chosen from the following:
A subject of the invention is still more particularly any pharmaceutical composition as defined above, characterized in that it comprises at least one peptide chosen from the following:
Advantageously, the above-mentioned pharmaceutical compositions of the invention, are characterised in that they are presented in a form which can be administered by systemic route (namely by intravenous, intramuscular, intraperitoneal, subcutaneous route), or non-invasively (for example by intranasal, oral, or epicutaneous route).
Advantageously also, the above-mentioned pharmaceutical compositions of the invention, are characterised in that the daily doses of peptides for a human are from approximately 100 ng to approximately 5 mg.
The invention also relates to the peptides comprising the sequence delimited by the amino acids 131 and 151 of the human or murine U1-70K protein, and corresponding to the sequence SEQ ID NO: 1 as follows: RIHMVYSKRSGKPRGYAFIEY
in which at least one of the amino acids is phosphorylated, or acetylated.
A subject of the invention is more particularly the above-mentioned peptides, comprising the sequence SEQ ID NO: 1 in which at least one of the serine residues in position 7 or 10 is phosphorylated, and/or at least one of the lysine residues in position 8 or 12 is acetylated.
The invention relates more particularly to the above-mentioned peptides, comprising the sequence SEQ ID NO: 1 in which:
The invention relates still more particularly to the following peptides:
A subject of the invention is still more particularly the following peptides:
The following are specific embodiments of the invention
Use of peptides comprising epitopes of self-proteins of mammals recognized by antibodies produced by the immune system of mammals suffering from autoimmune pathologies, and, if appropriate, by the auxiliary T cells of said mammals, said epitopes being such that at least one of their amino acids comprises a post-translational modification, for the preparation of a medicament intended for the prevention or treatment of said autoimmune pathologies.
Use of peptides according to embodiment 1, comprising epitopes at least one of the amino acids of which is modified so that it is in a phosphorylated, or acetylated form.
Use according to embodiment 1 or 2, of peptides comprising epitopes originating from proteins of human or animal origin defined in embodiment 1, chosen from nucleoproteins, proteins of the nucleosome, spliceosome, Ro ribonucleoproteic particle, or ribosome.
Use of peptides according to one of embodiments 1 to 3, for the preparation of a medicament intended for the prevention or treatment:
Use of peptides according to one of embodiments 1 to 4, for the preparation of a medicament intended for the prevention or treatment of SLE.
Use according to embodiment 5, of peptides comprising epitopes originating from the human or murine U1-70K protein of the spliceosome.
Use according to embodiment 5 or 6, of peptides comprising the sequence delimited by the 131 and 151 amino acids of the human or murine U1-70K protein, and corresponding to the following sequence SEQ ID NO: 1:
in which at least one of the amino acids comprises a post-translational-type modification, in particular by phosphorylation, or acetylation.
Use according to one of embodiments 5 to 7, of peptides comprising the sequence SEQ ID NO: 1 in which at least one of the serine residues in position 7 or 10 is phosphorylated, and/or at least one of the lysine residues in position 8 or 12 is acetylated.
Use according to one of embodiments 5 to 8, of peptides comprising the sequence SEQ ID NO: 1 in which:
Use according to one of embodiments 5 to 9, of peptides chosen from the following:
Use according to one of embodiments 5 to 10, of peptides chosen from the following:
Pharmaceutical composition characterized in that it comprises at least one peptide chosen from those defined in one of embodiments 1 to 11, in combination with a pharmaceutically acceptable vehicle.
Pharmaceutical composition according to embodiment 12, characterized in that it comprises at least one peptide chosen from those comprising the sequence SEQ ID NO: 1
in which at least one of the amino acids comprises a post-translational-type modification, in particular by phosphorylation, or acetylation.
Pharmaceutical composition according to embodiment 12 or 13, characterized in that it comprises at least one peptide chosen from those comprising the sequence SEQ ID NO: 1 in which at least one of the serine residues in position 7 or 10 is phosphorylated, and/or at least one of the lysine residues in position 8 or 12 is acetylated.
Pharmaceutical composition according to one of embodiments 12 to 14, characterized in that it comprises at least one peptide chosen from those comprising the sequence SEQ ID NO: 1 in which:
Pharmaceutical composition according to one of embodiments 13 to 15, characterized in that it comprises at least one peptide chosen from the following:
Pharmaceutical composition according to one of embodiments 13 to 16, characterized in that it comprises at least one peptide chosen from the following:
Pharmaceutical composition according to one of embodiments 13 to 17, characterized in that it is presented in a form which can be administered by systemic or non-invasive route.
Pharmaceutical composition according to one of embodiments 13 to 18, characterized in that the daily doses of peptides for a human are from approximately 100 ng to approximately 5 mg.
Peptides comprising the sequence delimited by the 131 and 151 amino acids of the human or murine U1-70K protein, and corresponding to the sequence SEQ in which at least one of the amino acids is phosphorylated, or acetylated.
Peptides according to embodiment 20, comprising the sequence SEQ ID NO: 1 in which at least one of the serine residues in position 7 or 10 is phosphorylated, and/or at least one of the lysine residues in position 8 or 12 is acetylated
Peptides according to embodiment 20 or 21, comprising the sequence SEQ ID NO: 1 in which:
Peptides according to one of embodiments 20 to 22, chosen from the following:
Peptides according to one of embodiments 20 to 23, chosen from the following:
The invention is further illustrated using the detailed description which follows of the synthesis of the modified peptides of the invention, as well as the study of their biological properties.
The phosphorylated peptides P137 (corresponding to the sequence SEQ ID NO: 1 in which the serine in position 7 is phosphorylated), and P140 (corresponding to the sequence SEQ ID NO: 1 in which the serine in position 10 is phosphorylated), and the Ac138 acetylated peptides (corresponding to the sequence SEQ ID NO: 1 in which the lysine in position 8 is acetylated), Ac142 (corresponding to the sequence SEQ ID NO: 1 in which the lysine in position 12 is acetylated), and Ac138+142 (corresponding to the sequence SEQ ID NO: 1 in which the lysine in position 8 and that in position 12 are acetylated), as well as the scrambled peptide Sc: YVSRYFGSAIRHEPKMKIYRG, and the scrambled peptide ScP corresponding to Sc in which the serine in position 8 is phosphorylated, (used as negative controls in the tests which follow) corresponding respectively to the sequence SEQ ID NO: 1 and to the P140 sequence in which the amino acids are in a different and random order, were chemically synthesized in solid phase on an automatic synthesizer using the Fmoc strategy (N-(9-fluorenyl)methoxycarbonyl). In order to introduce the phosphorylated serine residues in place of the serine residues or the acetylated lysine residues in place of the lysine residues, an Fmoc-Ser(PO(Obz)OH)—OH-type serine derivative, or an Fmoc-Lys (Ac)-type lysine derivative, were used. The coupling time is increased to 30 minutes and a second coupling is carried out systematically. After cleavage in acid medium, each peptide is precipitated by cold ether, solubilized in a solution of water and acetonitrile and finally lyophilized. The peptides are then purified by RP-HPLC, their integrity and their purity have been analyzed by analytic HPLC and by mass spectrometry (Maldi-TOF).
The HPLC profiles of the P137, P140, Ac138, Ac142, Ac138+142, Sc and ScP peptides are represented respectively in
The results are shown in Tables A, B, C, D, E, F and G below corresponding respectively to the HPLC profiles of the P137, P140, Ac 138, Ac 142, Ac 138+142, Sc and ScP peptides.
The mass spectra of the P137, P140, Ac 138, Ac 142, Ac 138+142, Sc and ScP peptides are represented respectively on
The 70K protein being strongly phosphorylated in vivo (Woppmann et al., 1993), and although the number of phosphorylated sites and their identity are not known, the inventors synthesized several peptides corresponding respectively to the phosphorylated and acetylated forms on the serine and lysine residues of the 131-151 peptide, and studied the capacity of these peptides to be recognized by the T lymphocytes and the antibodies of lupic mice.
The inventors demonstrate within the scope of the present invention that the phosphorylated peptide in position 140 is recognized to the same extent as or even to a greater extent than the non-phosphorylated peptide by the CD4+ T cells and the antibodies of lupic mice (
The inventors have demonstrated that the administration by intravenous route but not by intranasal route of the P140 phosphorylated peptide reduces the production of large numbers of antibodies directed against the DNA, delays the appearance of glomerulonephritis and prolongs the survival of animals (
Moreover, studies with 3 peptides acetylated on the lysines 138, 142 and 138+142 have been carried out. As in the case of the phosphorylated peptides, there is nothing allowing confirmation that these positions are really acetylated in vivo. The first results have shown that:
Finally the inventors have demonstrated that the 131-151 and P140 peptides were capable of binding various human MHC class II molecules (HLA-DR1, -DR4 and -DR11) (
| Number | Date | Country | Kind |
|---|---|---|---|
| 01/12041 | Sep 2001 | FR | national |
This application is a divisional of co-pending application Ser. No. 10/489,967 filed on Aug. 17, 2004, which is the 35 U.S.C. §371 national stage of International PCT/FR02/03186 filed on Sep. 18, 2002, which claims priority to French Application No. 01/12041 filed on Sep. 18, 2001. The entire contents of each of the above-identified applications are hereby incorporated by reference.
| Number | Date | Country | |
|---|---|---|---|
| Parent | 10489967 | Aug 2004 | US |
| Child | 12913232 | US |
